Quince Therapeutics, Inc. (QNCX) Form 8-K — Aug 27, 2026

$QNCXForm 8-KItems 5.02Filed Aug 27, 2026, 4:30 PM ET0001193125-26-371389Original filing

Quince Therapeutics reported that Charles Ryan, the company's President, will depart, with his last day of employment set for September 8, 2026. Ryan will be eligible for certain severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023, as disclosed in the Item 5.02 filing made August 27, 2026.

Price after filing

1 day: +3.8%7 days: -6.0%30 days: -4.6%

Close on the filing date to close N calendar days later (from $32.50). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.